ResearchGoserelin 3-Month Depot Shows Non-Inferiority to the Monthly Formulation in U.S. Patients with Premenopausal Breast Cancer: A Real-World Evidence Study
ResearchPilot Phase II Study of the Combination of Lenvatinib (L) and Eribulin (E) in Advanced Solid Tumors
ResearchTreatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States
ResearchSelection of Appropriate Biomarkers to Monitor Effectiveness of Ovarian Function Suppression in Pre-Menopausal Patients with ER+ Breast Cancer
ResearchIntegrated Multiomic Profiling of Breast Cancer in the Chinese Population Reveals Patient Stratification and Therapeutic Vulnerabilities
ResearchPhase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer
ResearchSacituzumab Govitecan in Patients with Breast Cancer Brain Metastases and Recurrent Glioblastoma: A Phase 0 Window-of-Opportunity Trial
ResearchElacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
ResearchBreast Cancer: The Good, the Bad, and an Important Call to Effective Risk Reduction Strategies
ResearchClinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study (preprint)